Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer

The primary purpose of this study is to determine what proportion of participants will achieve complete pathological response with epirubicin+ cyclophosphamide followed by docetaxel +carboplatin. This will also examine the potential of using signals in the blood (biomarkers) to identify resistance to chemotherapy in Nigerian women with triple negative breast cancer (TNBC). All enrollment to this trial will occur at sites in Nigeria. University of Chicago is serving as coordinating center and will be involved in data analysis.

Trial Details

NCT ID
NCT06291064
Phase
PHASE2
Sponsor
University of Chicago
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Cyclophosphamide
  • Epirubicin
  • Docetaxel
  • Carboplatin
  • Breast Surgery
  • Capecitabine
Locations (sample)
  • Ikeja, Lagos, Nigeria|6.59651,3.34205
  • Yaba, Lagos, Nigeria|6.51395,3.37389
  • Ile-Ife, Osun State, Nigeria|7.4824,4.56032
  • Ibadan, Oyo State, Nigeria|7.37756,3.90591

Key Eligibility Criteria

  • Women ages of 18 to 70 years old
  • Women who are able and willing to read understand and sign an informed consent document
  • Biopsy-accessible breast tumor of significant size for core needle biopsy/ultrasound measurable (≥ 2cm)
  • Patients with histologically confirmed carcinoma of the female breast with triple-negative status by immunohistochemistry (IHC). Patients who are l…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →